148 related articles for article (PubMed ID: 37474746)
1. Significance of O6-methyl guanine methyltransferase promoter methylation in high grade glioma patients: optimal cutoff point, CpG locus, and genetic assay.
Buyuktepe M; Kaplan I; Bayatli E; Dogan H; Ugur HC
J Neurooncol; 2023 Aug; 164(1):171-177. PubMed ID: 37474746
[TBL] [Abstract][Full Text] [Related]
2. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
3. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
4. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
6. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
Haque W; Teh C; Butler EB; Teh BS
J Neurooncol; 2022 Mar; 157(1):137-146. PubMed ID: 35103907
[TBL] [Abstract][Full Text] [Related]
10. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
[TBL] [Abstract][Full Text] [Related]
11. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.
Brigliadori G; Foca F; Dall'Agata M; Rengucci C; Melegari E; Cerasoli S; Amadori D; Calistri D; Faedi M
J Neurooncol; 2016 Jun; 128(2):333-9. PubMed ID: 27029617
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
[TBL] [Abstract][Full Text] [Related]
13. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
Gömöri E; Pál J; Kovács B; Dóczi T
Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
[TBL] [Abstract][Full Text] [Related]
14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
15. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
[TBL] [Abstract][Full Text] [Related]
16. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
[TBL] [Abstract][Full Text] [Related]
17. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
[TBL] [Abstract][Full Text] [Related]
18. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
19. Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing.
Halldorsson S; Nagymihaly RM; Patel A; Brandal P; Panagopoulos I; Leske H; Lund-Iversen M; Sahm F; Vik-Mo EO
Neuropathol Appl Neurobiol; 2024 Jun; 50(3):e12984. PubMed ID: 38783575
[TBL] [Abstract][Full Text] [Related]
20. The Significance of
Jovanović N; Lazarević M; Cvetković VJ; Nikolov V; Kostić Perić J; Ugrin M; Pavlović S; Mitrović T
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
